Related Experiment Video

Updated: Jun 16, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Experience with fulvestrant acetate in castration-resistant prostate cancer patients

J M Gasent Blesa, V Alberola Candel, V Giner Marco

    Annals of Oncology : Official Journal of the European Society for Medical Oncology
    |February 9, 2010
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Focal Laser Ablation of Prostate Cancer: An Office Procedure
    11:07

    Focal Laser Ablation of Prostate Cancer: An Office Procedure

    Published on: March 30, 2021

    Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
    09:49

    Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

    Published on: December 28, 2021

    Related Experiment Videos

    Last Updated: Jun 16, 2026

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    Focal Laser Ablation of Prostate Cancer: An Office Procedure
    11:07

    Focal Laser Ablation of Prostate Cancer: An Office Procedure

    Published on: March 30, 2021

    Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
    09:49

    Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

    Published on: December 28, 2021

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2021

    Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2021

    Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis.

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2018

    SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma.

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2015

    SEOM clinical guidelines for the treatment of Hodgkin's lymphoma.

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2015

    Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice.

    European journal of cancer care·2013

    Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Thymic Radiation is Associated with Worse Outcomes in Patients with NSCLC.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    CAR-Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune-Mediated Inflammation.

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

    Ivonescimab in combination with chemotherapy in advanced or metastatic gastric cancer (GC) or esophagogastric junction cancer (EGJC): The UCGI 52 - GRACIE trial.

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026

    [Predictors of treatment-free remission (TFR) and second TFR attempts in chronic myeloid leukemia].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·2026

    [Aplastic anemia developed after treatment with durvalumab].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·2026

    [Development of memory-like CAR-NK cells with durable antitumor activity].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·2026

    Curcumin Suppresses Growth of Recurrent Colorectal Adenoma After Endoscopic Resection: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.

    The American journal of gastroenterology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us